Press release
BPH Surgical Treatment Market worth $17.19 billion in 2030

Prominent players in the BPH Surgical Treatment market drug type include GlaxoSmithKline PLC (UK), Eli Lilly and Company (US), Astellas Pharma Inc.(Japan), Viatris Inc. (US), Asahi Kasei Corporation (Japan), Organon & Co. (US), Alembic Pharmaceuticals Lim
The global [https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket], valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in 2024 and an impressive US$17.19 billion by 2030. Benign prostatic hyperplasia is a condition in males in which the prostate is enlarged, leading to difficulty in urinating. The growing incidence of benign prostatic hyperplasia (BPH) cases is expected to drive the demand for Benign Prostatic Hyperplasia Surgical Treatment. The aging population is a global demographic trend characterized by an increasing proportion of older individuals due to longer life expectancy and declining birth rates. The rising incidence of obesity in males is also expected to increase the incidence of BPH as the two factors are closely associated. Obesity leads to several issues, such as rising sympathetic nervous activity, altered endocrine status, increased intra-abdominal pressure, increased inflammation process, and oxidative stress, favorable conditions for developing BPH. However, the growing preference for minimally invasive surgeries is considered adequate, providing reduced recovery times and fewer complications compared to traditional surgery. Additionally, the high growth potential of emerging economies, along with the favorable funding investments for BPH drug development, are expected to provide lucrative growth opportunities for market players.
Download PDF Brochure: [https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=198000374&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket]
Browse in-depth TOC on "Benign Prostatic Hyperplasia Surgical Treatment Market"
368 - Tables
59 - Figures
328 - Pages
Based on drug type, the global Benign Prostatic Hyperplasia Surgical Treatment market can be divided into three segments: alpha-blockers (-blockers), 5-alpha reductase inhibitors (5-ARIs), and other drug types [combination drugs, muscarinic receptor antagonists (MRAs), and phosphodiesterase 5 (PDE5) inhibitors]. The alpha-blockers (-blockers) category is expected to have the highest CAGR from 2024 to 2030. Factors driving the growth of alpha-blockers (-blockers), include an aging population. Alpha-blockers (-blockers) are recommended as first-line treatment for BPH as it relax the smooth muscle of the prostate and bladder neck to improve urine flow and reduce bladder outlet obstruction. These are highly efficient drugs, such as monotherapy, in treating BPH-associated lower urinary tract symptoms (LUTS).
The Benign Prostatic Hyperplasia Surgical Treatment market, by type, is segmented into Transurethral Resection of the Prostate (TURP), Laser Surgery, UroLift Procedure, Rezum Procedure, Robot-assisted Waterjet Ablation, Prostatic Stenting, Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Prostatic Arterial Embolization (PAE) and Other Procedures. The Transurethral Resection of the Prostate (TURP) segment is anticipated to witness the highest growth rate during the forecast period. This is because TURP, a well-established and cost-effective first-line preferred treatment procedure, is often covered by insurance and is typically less expensive than newer options regarding the procedure and hospital stay.
Based on therapy, the Benign Prostatic Hyperplasia Surgical Treatment market is segmented into monotherapy and combination drug therapy. In the upcoming years, monotherapy is expected to grow at the fastest rate because to the rising prevalence BPH patients, cost efficiency, and convenience in treating BPH. Low risk of side effects and drug interactions, significantly improving the quality of life.
Based on the type of end-user, the Benign Prostatic Hyperplasia Surgical Treatment market is divided into hospitals, ambulatory surgery centers & clinics, and home care setting. Between 2024 and 2030, the home care setting segment is predicted to expand at the fastest rate. The growth rate of the home care setting segment can be attributed to the large patient population of individuals being administered medication in the convenience and efficiency of indoor settings. Medications like alpha-blockers or 5-alpha reductase inhibitors can be taken orally, contributing to market growth.
The global Benign Prostatic Hyperplasia Surgical Treatment market has been segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC countries. The Asia Pacific region is expected to witness the highest growth rate during the forecast period.
North America is the largest regional market for BPH treatment. The North American market comprises the US and Canada. The rising geriatric and obese population and the availability of research funding are the major factors driving the market growth. Initiatives by key players are also expected to contribute to the market. The large share of the US in the North American BPH treatment market can be mainly attributed to the growing target population, the high incidence of BPH, and the strong presence of medical device manufacturers. Additionally, favorable reimbursement policies, high disposable incomes, a strong and improved healthcare infrastructure, research funding, and product launches.
The US has a strong healthcare system with advanced infrastructure. The robust healthcare infrastructure, combined with specialized healthcare facilities and a rising number of hospitals which drives the Benign Prostatic Hyperplasia Surgical Treatment market in the country. The growing geriatric population along with an increasing number of BPH cases is supporting the Benign Prostatic Hyperplasia Surgical Treatment market growth.
The funding supports the development of cutting-edge technologies like Robotic waterjet assistance which are increasingly shaping the BPH treatment landscape. For instance, Zenflow, Inc., a US-based medical device company that is developing a minimally invasive treatment for urinary obstruction caused by, benign prostatic hyperplasia announced that it has closed a USD 24 million Series C financing round. The round includes new investor Cook Medical as well as existing investors Indus Opportunities, F-Prime Capital, Medical Technology Venture Partners, and others.
Request Sample Pages : [https://www.marketsandmarkets.com/requestsampleNew.asp?id=198000374&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket]
The Benign Prostatic Hyperplasia Surgical Treatment market is consolidated, with top companies holding significant market shares. The top three players in the drug type market include GlaxoSmithKline PLC (UK) Astellas Pharma Inc. (Japan) and Viatris Inc. (US. Also, the top three players in the type of market includes Teleflex Incorporated (US), Boston Scientific Corporation (US), and Olympus Corporation (Japan) dominating the market.
Players in this market are focusing on adopting organic and inorganic growth strategies such as product approvals, acquisitions, agreements, partnerships, and other developments such as regulatory approvals to increase their BPH treatment products portfolio, cater to customer needs, increase their profitability and expand their presence in the global Benign Prostatic Hyperplasia Surgical Treatment market.
By Drug Type
Viatris Inc. (US) is the leading player contributing a share of 10-12% in 2023 in the Benign Prostatic Hyperplasia Surgical Treatment Market The company offers 1,400 approved molecules of various therapeutic areas which includes key brands and generics recognized globally. The brand division caters to the BPH surgical products market, i.e., Apha1 adrenergic antagonist known as CARDURA (doxazosin).
GlaxoSmithKline PLC (UK) is the second leading Benign Prostatic Hyperplasia Surgical Treatment market player, with a 6.0-8.0% share in 2023. The Commercial Operations segment has three product groups: Vaccines, Specialty Medicines, and General Medicines. The company offers various products to treat chronic & acute diseases. The products for BHP treatment are provided through its General Medicines product group under the Commercial Operations segment. The company offers 5-Alpha-Reductase Inhibitors by the brand name Avodart and a combination drug with dutasteride 500 g and 400 g tamsulosin hydrochloride by the brand name Duodart. In July 2023, GlaxoSmithKline PLC and Recordati entered into an agreement with GSK to commercialize Avodart (dutasteride) and Combodart/Duodart (dutasteride/tamsulosin) across 21 countries, mainly in Europe, excluding only those where GSK already has a distribution agreement in place.
Astellas Pharma Inc. (Japan) In the Benign Prostatic Hyperplasia Surgical Treatment market the company accounts for a share of around 4-6% in 2023. Pharmaceutical products are manufactured and marketed by a single business segment. Th key segments targeted are immunology, anti-infectives, oncology, urology, and metabolic applications. The company provides alpha blocker Harnal (Tamsulosin hydrochloride) for the treatment BPH by the Urology category. The company have a global presence in around 40 countries across the world.
By Type
Boston Scientific Corporation (US) is the leading Benign Prostatic Hyperplasia Surgical Treatment market player, with a share of 9.0-10.0% in 2023. The various procedures offered by the company include Greenlight XPS Laser System, Moxy Fiber, and Rezum Systems for treating BPH.
Teleflex Incorporated (US) is ranked as the second leading player in the Benign Prostatic Hyperplasia Surgical Treatment market. In 2023, The company is contributing a share of 8.0-9.0% in 2023. The Interventional Urology segment offers the UroLift System which is a minimally invasive technology benign prostatic hyperplasia. The company has also introduced the UroLift system in China to make notable progress in advancing other high-growth products and line extensions through the regulatory process.
Olympus Corporation (Japan) accounted for a share of 8.0% in 2023 in the Benign Prostatic Hyperplasia Surgical Treatment market. The underlying high-frequency technology of PLASMA has been used for over 17 years. It offers proven therapy for patients with benign prostatic hyperplasia (BPH) and expanded reimbursement for differentiated MIS BPH devices, which provide better clinical outcomes and elevate the standard of care.
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
We have selected six market vendors based on their capabilities, innovations, product offerings, and business strategies. A comprehensive list of all the vendors in this market was created through a product mapping strategy and MarketsandMarkets analysis. Our selected vendor mix includes companies from Tier 1-Tier 4 to cover the Benign Prostatic Hyperplasia Surgical Treatment market. Based on their performance in each criterion, the vendors are divided into four categories: Stars, Emerging Leaders, Omnipresent Players, and Participants.
For more information, [https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=198000374&utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket]
Media Contact
Company Name: MarketsandMarkets Trademark Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bph-surgical-treatment-market-worth-1719-billion-in-2030]
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release BPH Surgical Treatment Market worth $17.19 billion in 2030 here
News-ID: 3908096 • Views: …
More Releases from ABNewswire

Fibrodysplasia Ossificans Market to Experience Notable Growth in Forecast Span b …
The Key Fibrodysplasia Ossificans Progressiva Companies in the market include - Ipsen, Regeneron Pharmaceutical, Biocryst,, and others.
The Fibrodysplasia Ossificans Progressiva market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibrodysplasia Ossificans Progressiva pipeline products will significantly revolutionize the Fibrodysplasia Ossificans Progressiva market dynamics.
DelveInsight's "Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of…

Diabetic Macular Edema Pipeline 2025: MOA and ROA Insights, Clinical Trials Stat …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Macular Edema pipeline constitutes key companies continuously working towards developing Diabetic Macular Edema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Diabetic Macular Edema Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/diabetic-macular-edema-dme-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Macular Edema Market.
The Diabetic Macular…

FIELDBOSS Secures Top Ranking as #1 Elevator Service Software, Recognized for In …
AVENTURA, FL - September 2, 2025 - FIELDBOSS has been named the #1 software for the elevator and escalator industry, winning the top honor from the independent review body, Field Service Software IO. The award distinguishes FIELDBOSS in a competitive market for its ability to manage the complex compliance, maintenance, and operational demands unique to the vertical transportation industry.
The significance of the award is underscored by the selection process. Field…

Progressive Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till …
The Key Progressive Pulmonary Fibrosis Companies in the market include - Boehringer Ingelheim, Bristol-Myers Squibb, Avalyn Pharma Inc., United Therapeutics, Sunshine Lake Pharma, Endeavor Biomedicines, and others.
The Progressive Pulmonary Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Progressive Pulmonary Fibrosis pipeline products will significantly revolutionize the Progressive Pulmonary Fibrosis market dynamics.
DelveInsight's "Progressive Pulmonary Fibrosis Market Insights,…
More Releases for BPH
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Benign Prostatic Hyperplasia (BPH) Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The benign prostatic hyperplasia (BPH) treatment market is experiencing significant growth due to the rising prevalence of BPH among the aging male…
How big is Benign Prostate Hyperplasia (BPH) Market?
Benign Prostate Hyperplasia (BPH) Market is forecasted to reach at a CAGR of 6% during the forecast period (2024-2031).
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Benign Prostate Hyperplasia (BPH) market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market…
Laser BPH Devices Market Expected to Reach $765.4 Million by 2031
Laser BPH devices market was valued at $460.25 million in 2021, and is estimated to reach $765.4 million by 2031, growing at a CAGR of 5.2% from 2022 to 2031. Prostate enlargement, commonly known as benign prostatic hyperplasia (BPH), is a noncancerous expansion of the prostate gland. Frequent urination, difficulty starting to urinate, a weak stream, the inability to urinate, or a loss of bladder control are examples of symptoms.…
Benign prostatic hyperplasia: BPH drugs versus Dr Allen’s Device
The Global Treatment Market of Benign prostatic hyperplasia (BPH) was valued at $10,688.72 million in 2017 and is projected to reach $20,096.68 million by 2025 at a CAGR of 8.1% from 2018 to 2025.
Thermobalancing therapy with Dr Allen’s Device was patented by the United States Patent and Trademark Office. Over a decade, thousands of men with BPH used or are using this non-invasive and side-effects free Dr Allen’s Device.…